Intense competition in CRO has reduced gross margin. Sunlight Nuohe is entering the animal health field to seek new growth points.

①Sun Pharmaceuticals' revenue and net income for the first three quarters of this year have increased compared to the past, but the fierce competition in the industry has led to a decline in gross margin. The chairman revealed that the company is increasing research and development investment. ②In order to find new growth opportunities, Sun Pharmaceuticals has established a subsidiary to further expand its CRO business from the human pharmaceutical field to the animal health field, and has signed service orders with several large animal pharmaceutical companies.

cls.cnDec 2 15:59

Key stock indices in Hong Kong, major adjustments! 570 billion funds, embracing "change"!

Hang Seng Index latest adjustment! Today, Hang Seng Indexes Company Limited announced that Kuaishou Technology, new oriental education technology group will be included in the Hang Seng Index, while New World Development Company will be removed. The number of constituent stocks in the Hang Seng Index will increase from 82 to 83; China people's property insurance co., ltd. will be included in the Hang Seng H-Share Index ETF, while Longfor group holdings limited will be removed. The number of constituent stocks in the Hang Seng H-Share Index ETF will remain at 50; Midea Group Co., Ltd will be included in the Hang Seng Tech Index, while Weibo Co., Ltd. will be removed. The number of constituent stocks in the Hang Seng Tech Index will remain at 40. Hang Seng Indexes Company Limited stated that all changes will take effect in 2024.

China brokerageNov 22 21:17

Foreign public fund latest hold positions exposure! Fund managers are bullish on china's stock market valuation repair.

With the disclosure of the third quarter report, public funds under international asset management giants such as BlackRock and Fidelity have all their holdings exposed.

Securities TimesOct 29 10:07

The first gene therapy CDMO stock cannot break out of the loss "vortex"! HUYA Bio had a net loss of 0.19 billion in the first three quarters.

①He Yuan Biology is still deeply mired in the vortex of losses, with a net loss of 0.19 billion yuan attributable to owners in the first three quarters of this year, a year-on-year decrease of 166.90%, compared to a net loss of 71.0996 million yuan in the same period last year. ②He Yuan Biology revealed that customers are more price sensitive due to limited financing, and the prices of different types of CDMO orders are at historically low levels.

cls.cnOct 24 07:48

Benefiting from the growth in sales of peptide active pharmaceutical ingredients, Neutai Life Sciences' Q3 net income increased by 147%.

Benefiting from significant growth in revenue from polypeptide APIs, Novatek Bio achieved a net income attributable to equity holders of 0.123 billion yuan in Q3, a year-on-year increase of 146.86%, previously expected to have a maximum growth of 180.78%. With the GLP-1 drugs sparking a craze in the weight loss field, coupled with indications for lowering blood sugar, the GLP-1 drug market is rapidly expanding, driving the development of related polypeptide API enterprises.

cls.cnOct 23 08:03

Existing for over 14 years, Yunfeng RMB Fund Phase I may successfully come to an end.

①Shanghai Yunfeng has had a commercial change, with the registered capital reduced from 0.29 billion RMB to 10 million RMB; ②Yunfeng Fund stated that it has currently established five batches of RMB investment funds and four batches of USD investment funds. The settlement of early funds indicates that the company is further optimizing its strategy and portfolio, strengthening the investment layout of subsequent funds.

cls.cnOct 22 17:14